telisotuzumab,vedolizumab,abbv-399
abbvie,takeda
['teliso-v', 'lung', 'nsclc', 'lcsm,(-blcsm)', 'telisotuzumab vedotin', 'teliso', 'vedo', 'sclc', ' vedo']
tps9149: phase 2 study of telisotuzumab vedotin (teliso-v) monotherapy in patients with previously untreated met amplified locally advanced/metastatic non-squamous non-small cell lung cancer (nsq nsclc). met-specialist adc for met amp. #asco23 #lcsm 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC